APOA5 Antikörper (C-Term)

Produktnummer ABIN375169

Dieser Ziege Polyklonal Antikörper detektiert spezifisch APOA5 in WB und EIA. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für APOA5 Antikörper (C-Term) (ABIN375169)

Target: APOA5 (Apolipoprotein A-V (APOA5))

Reaktivität: Human

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser APOA5 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Produktdetails anti-APOA5 Antikörper

Bindungsspezifität: C-Term

Spezifität: This antibody reacts to APOA5.

Aufreinigung: Affinity chromatography

Immunogen: Peptide with sequence C-HSLHDQGHSHLGDP, from the C Terminus of the protein sequence

Anwendungsinformationen

Applikationshinweise: Peptide ELISA: 1/64000. Western Blot: 0.3 - 1 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0,5 mg/mL

Buffer: Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu APOA5

Target: APOA5 (Apolipoprotein A-V (APOA5))

Andere Bezeichnung: Apolipoprotein A V (ApoA V)

Hintergrund: Apolipoprotein A V is a minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. It may also be associated with chylomicrons. It is an important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate). Apolipoprotein A V activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Apolipoprotein A V is upregulated by PPARA agonists, which are used clinically to lower serum TG (such as fibrates). It is induced in early phase of liver regeneration. Defects in Apolipoprotein A V gene are a cause of susceptibility to familial hypertriglyceridemia. It is a coronary heart disease risk factor. On a regular diet the patient demonstrates increased plasma VLDL. Plasma triglycerides are persistently increased, while plasma cholesterol and phospholipids are usually within normal limits.Synonyms: APOA5, Apo-AV, ApoA-V, Apolipoprotein A-V, RAP3, Regeneration-associated protein 3

Gen-ID: 116519, 9606

UniProt: Q6Q788

Pathways: Regulation of Lipid Metabolism by PPARalpha, Lipid Metabolism